Trial Profile
A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients With Relapsed/Refractory Glioma Positive for an FGFR Fusion
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Acronyms TARGET
- 24 May 2019 Status changed from suspended to completed.
- 10 Apr 2019 This trial has been completed in France.
- 01 Mar 2018 Planned End Date changed from 1 Nov 2017 to 1 Sep 2018.